UCB Announces the Approval of CIMZIA (Certolizumab Pegol) for Moderate-to-Severe Plaque Psoriasis, Representing an Important New Option for Patients in the U.S.

  • Alice Gottlieb

Press/Media

Period27 May 2018 → 29 May 2018

Media coverage

2

Media coverage

  • TitleUCB Announces the Approval of CIMZIA (Certolizumab Pegol) for Moderate-to-Severe Plaque Psoriasis, Representing an Important New Option for Patients in the U.S.
    Media name/outletPharmacy Choice
    Country/TerritoryUnited States
    Date29/05/18
    URLwww.pharmacychoice.com/news/article.cfm?Article_ID=2018115
    PersonsAlice Gottlieb
  • TitleUCB Announces the Approval of CIMZIA (Certolizumab Pegol) for Moderate-to-Severe Plaque Psoriasis, Representing an Important New Option for Patients in the U.S.
    Media name/outletTargeted News Service
    Country/TerritoryUnited States
    Date27/05/18
    PersonsAlice Gottlieb